Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001982097 | SCV002212234 | uncertain significance | Primary dilated cardiomyopathy | 2021-08-07 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant is not present in population databases (ExAC no frequency). This sequence change replaces arginine with histidine at codon 418 of the TXNRD2 protein (p.Arg418His). The arginine residue is weakly conserved and there is a small physicochemical difference between arginine and histidine. This variant has not been reported in the literature in individuals affected with TXNRD2-related conditions. |
Ambry Genetics | RCV002423089 | SCV002676564 | uncertain significance | Cardiovascular phenotype | 2021-11-14 | criteria provided, single submitter | clinical testing | The p.R418H variant (also known as c.1253G>A), located in coding exon 14 of the TXNRD2 gene, results from a G to A substitution at nucleotide position 1253. The arginine at codon 418 is replaced by histidine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |